SGLT2 inhibitors and risk of genitourinary infections

Abstract

The SGLT2 inhibitors dapagliflozin, canagliflozin and empagliflozin are now becoming established in the management of type 2 diabetes, but they are associated with an increased risk of genital and urinary tract infections, compounding the problem that people with diabetes are already at higher risk than the general population. This article examines the extent of these risks and how they may affect treatment adherence.